Ian Ingram is a Deputy Managing Editor at MedPage Today. He specializes in medicine and healthcare, with a focus on medical specialties such as endocrinology, oncology, immunotherapy, radiation oncology, mental health care, surgery, and hematology. Ian's work has been featured in Knowledia, ExBulletin, MSN, and MedPage Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ian Ingram's coverage is primarily focused on healthcare and pharmaceuticals, with a particular emphasis on clinical trial results, FDA approvals, and drug treatments for cancer and leukemia. He frequently cites data in his articles, indicating an interest in evidence-based reporting.
Pitching to Ian should involve providing access to newly released or exclusive clinical trial data, insights from key opinion leaders in the field of oncology or pharmaceuticals regarding recent developments in cancer treatment or FDA approval processes.
It's important to note that Ian does not have a specific geographic focus but covers international healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Cases have included chronic, neurodegenerative encephalitis that played out over months to years
By: Ian Ingram
U.S. poison centers reported a nearly fourfold increase in calls for liver injury opens in a new tab or window from 2000 to 2024, with
By: Ian Ingram
— News and commentary from the world of gastroenterology and hepatology
— Trial data showed significant increases in durable hemoglobin responses versus placebo
Patients with GSDIa need to constantly eat cornstarch to avoid drops in blood sugar
Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug
By: Ian Ingram
Virginia gastroenterologist Krista Edelman, MD, went viral on social media opens in a new tab or window after revealing she woke up to a bat trying to burrow its way into her mouth. ( People
— Possible risks include aspiration, esophageal lacerations, and blood loss, agency says
By: Ian Ingram
The FDA said it expanded approval opens in a new tab or window of the interleukin (IL)-12/23 antagonist ustekinumab (Stelara) to include treatment
By: Ian Ingram
News and commentary from the world of gastroenterology and hepatology
